A. J. Kazimi
Net Worth
Last updated:
What is A. J. Kazimi net worth?
The estimated net worth of Mr. A. J. Kazimi is at least $30,594,798 as of 29 Nov 2024. He owns shares worth $17,902,795 as insider, has earned $100,003 from insider trading and has received compensation worth at least $12,592,000 in Cumberland Pharmaceuticals Inc..
What is the salary of A. J. Kazimi?
Mr. A. J. Kazimi salary is $787,000 per year as Founder, Chairman, Pres & Chief Executive Officer in Cumberland Pharmaceuticals Inc..
How old is A. J. Kazimi?
Mr. A. J. Kazimi is 67 years old, born in 1958.
What stocks does A. J. Kazimi currently own?
As insider, Mr. A. J. Kazimi owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Cumberland Pharmaceuticals Inc. (CPIX) | Founder, Chairman, Pres & Chief Executive Officer | 5,701,527 | $3.14 | $17,902,795 |
What does Cumberland Pharmaceuticals Inc. do?
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
A. J. Kazimi insider trading
Cumberland Pharmaceuticals Inc.
Mr. A. J. Kazimi has made only one insider trade between 2009-2024, according to the Form 4 filled with the SEC. He purchased 75 units of CPIX stock worth $99 on 29 Nov 2024.
As of 29 Nov 2024 he still owns at least 5,701,527 units of CPIX stock.
Cumberland Pharmaceuticals key executives
Cumberland Pharmaceuticals Inc. executives and other stock owners filed with the SEC:
- Mr. A. J. Kazimi (67) Founder, Chairman, Pres & Chief Executive Officer
- Mr. James Lowrance Herman (70) Senior Vice President of National Accounts & Chief Compliance Officer
- Mr. Leo B. Pavliv (64) Executive Vice President of Operations & Chief Devel. Officer
- Mr. Martin E. Cearnal (80) Executive Vice President, Chief Commercial Officer & Director